DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration
Rockville MD 20857

NDA 16-647/S-035

JUL 1 1998

Berlex Drug Development & Technology
Attention: Ms. Nancy A. Konnerth
340 Changebridge Road
P.O. Box 1000
Montville, NJ 07045-1000

Dear Ms. Konnerth:

Please refer to your May 12, 1998 supplemental new drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Quinaglute Dura-Tabs (quinidine gluconate) 324 mg Tablets.

We also acknowledge receipt of your May 22, 1998 submission.

This supplemental new drug application provides for final printed labeling revised under PRECAUTIONS/Drug Interactions for addition of a statement regarding a drug interaction between quinidine and diltiazem. Under HOW SUPPLIED, the "CAUTION: Federal (USA) law prohibits dispensing without prescription" statement has been changed to "Rx Only."

We have completed the review of this supplemental application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the final printed labeling included in your May 12, 1998 submission. Accordingly, the supplemental application is approved effective on the date of this letter.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

At the time of your next printing, please make the following changes:

1. In the first sentence of the second paragraph under PRECAUTIONS/Drug Interactions/Non-interaction of quinidine with other drugs, the word "diltiazem" should be deleted between the words "digoxin" and "felodipine." This sentence should state:

   > Conversely, the pharmacokinetics of quinidine are not significantly affected by caffeine, ciprofloxacin, digoxin, felodipine, omeprazole, or quinine.

2. Under OVERDOSAGE/Accelerated removal, the word “diltiazem” should be added to the fourth paragraph. This sentence should state:

> Following quinidine overdose, drugs that delay elimination of quinidine (cimetidine, carbonic-anhydrase inhibitors, diltiazem, thiazide diuretics) should be withdrawn unless absolutely required.

3. Under HOW SUPPLIED, we recommend that the Storage Statement be changed to:

> Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)
> [See USP Controlled Room Temperature.]

If you have any questions, please contact:

Ms. Diana Willard
Regulatory Health Project Manager
(301) 594-5311

Sincerely yours,

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Drug Interactions

Altered pharmacokinetics quinidine: Diltiazem significantly decreases the clearance and increases the $t_{1/2}$ of quinidine, but quinidine does not alter the kinetics of diltiazem.